Unfractionated heparin dosing for therapeutic anticoagulation in critically ill obese adults

J Crit Care. 2015 Apr;30(2):395-9. doi: 10.1016/j.jcrc.2014.11.020. Epub 2014 Dec 3.

Abstract

Purpose: Research evaluating unfractionated heparin (UFH) dosing in obese critically ill populations is limited. This study aimed to determine optimal weight-based and total therapeutic infusion rates of UFH in this population.

Methods: This retrospective cohort study compared adults on UFH infusions in intensive care units from May 2011 through October 2013 across 3 weight strata: 95 to 104 kg (control), 105 to 129 kg (high weight), and greater than or equal to 130 kg (higher weight). Primary outcomes included total and weight-based infusion rates for therapeutic anticoagulation.

Results: To achieve therapeutic activated partial thromboplastin times, higher weight patients had higher mean infusion rates compared with control (2017 vs 1582 U/h; P = .002). Mean weight-based therapeutic infusion rate was lower in the higher weight group compared with control (13.1 vs 15.8 U kg(-1) h(-1); P = .008). Post hoc analyses indicated mean weight-based infusion rate to achieve therapeutic anticoagulation was 15 U kg(-1) h(-1) in patients less than 165 kg and 13 U kg(-1) h(-1) in patients greater than 165 kg.

Conclusions: Patients greater than or equal to 130 kg have lower weight-based heparin requirements compared with patients 95 to 104 kg. This difference appears to be driven by patients greater than 165 kg. Patients greater than 165 kg have lower weight-based heparin requirements, whereas patients from 105 to 164 kg have weight-based requirements similar to a normal-weight patient population. Initiating heparin at appropriate weight-based doses for obese patients may optimize anticoagulation.

Keywords: Anticoagulation; Critically ill; Heparin; Obesity.

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / administration & dosage*
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Cohort Studies
  • Comorbidity
  • Critical Illness
  • Female
  • Heparin / administration & dosage*
  • Humans
  • Infusions, Intravenous
  • Intensive Care Units
  • Male
  • Middle Aged
  • Obesity / complications*
  • Partial Thromboplastin Time
  • Pulmonary Embolism / complications
  • Pulmonary Embolism / drug therapy*
  • Retrospective Studies
  • Time Factors
  • Venous Thromboembolism / complications
  • Venous Thromboembolism / drug therapy*

Substances

  • Anticoagulants
  • Heparin